bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.01.21.477254

The evolution of BDNF is defined by strict purifying selection and prodomain spatial coevolution, but what does it mean for human brain disease?

Abstract

The mammalian gene Brain-Derived Neurotrophic Factor (BDNF) is an essential mediator of brain assembly, development, and maturation which has been implicated in a variety of brain disorders such as neurodevelopmental disorders (e.g. autism spectrum disorder), neuropsychiatric disorders (e.g. depression, PTSD, schizophrenia), and neurodegenerative disorders (e.g. Parkinsons). Loss of BDNF during early development is embryonic lethal, and depletion of BDNF during adolescence or adulthood can result in disease-related neuropathology across a broad range of model organisms. In order to better understand the role of BDNF in disease, we seek to provide an evolutionary context to BDNFs role within the brain by elucidating the molecular and genetic comparative history of BDNF across species. We conduct sequence alignment and phylogenetic reconstruction of the BDNF gene across a diverse selection of over 160 mammalian species spanning [~]177 million years of evolution. Selective evolutionary change was examined via several independent computational models of codon evolution including FEL, MEME, and BGM. We report strict purifying selection in the main functional domain of BDNF (NGF domain, essentially comprising the mature BDNF protein). Specifically, we discover 6 sites in our homologous alignment which are under episodic selection in the early regulatory region of BDNF (i.e. the prodomain) and 23 pairs of coevolving sites that are a part of complex spatial relationships that are distributed across the entire BDNF gene. Thus, we propose that our discovery of both local and distal sites of co-evolution within the pro- and mature-domains of BDNF that likely reflect the evolutionary fine-tuning of BDNFs unique and complex regulatory capacities whilst also retaining its core yet diverse ontogenic functionality within the central nervous system. This discovery consequently supports the idea that the BDNF prodomain is more prone to change than the mature domain, however the fact that this region has also been subject to negative purifying selection also highlights genetic sensitivity and thus partially explains the prodomains disease relevance (e.g. Val66Met and other variants) to numerous neuropsychiatric disorders. HIGHLIGHTSO_LIWe extracted coding sequences for Brain-Derived Neurotrophic Factor (BDNF) from over 160 mammalian genomes that span approximately [~]177 million years of evolution. C_LIO_LIWe observe strict purifying selection in the main functional domain (NGF) of the BDNF gene in mammals. C_LIO_LIWe observe novel results with 6 sites in our homologous alignment which are under episodic selection in the early regulatory region of BDNF (i.e. the prodomain). C_LIO_LIWe observe 23 pairs of coevolving sites within BDNF. Many of which are a part of complex spatial relationships and are distributed across the entire BDNF gene. C_LIO_LIThese data define exactly how "BDNF is highly conserved" by defining exactly where and how the mammalian BDNF has evolved, confirming the widespread belief that the BDNF prodomain is more prone to change than the mature BDNF protein. C_LI

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lucaci, A. G., Notaras, M., Kosakovsky Pond, S. L., Colak, D.. 2022-01-21. The evolution of BDNF is defined by strict purifying selection and prodomain spatial coevolution, but what does it mean for human brain disease?. https://doi.org/10.1101/2022.01.21.477254

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Epidermal Langerhans Cells Act as Neuroimmune Regulators of Pain and Itch

Neuroimmune interactions in the skin coordinate immune defense and somatosensory perception, yet how immune cells shape sensory signaling remains poorly defined. Here, we show that Langerhans cells (LCs), epidermal antigen-presenting cells, function as local immune-derived amplifiers of cutaneous sensory signaling. Anatomical and transcriptomic analyses reveal preferential LC association with non-peptidergic sensory neurons. LC activation increases neuronal and behavioral responses to thermal, mechanical, and pruritic stimuli without directly exciting sensory neurons, whereas LC inhibition or ablation selectively reduces pruritogen-evoked itch. We identified semaphorin 7A as a candidate LC-expressed mediator. Semaphorin 7A sensitized cultured sensory neurons to chloroquine and histamine, and neutralizing semaphorin 7A abolished the increase in chloroquine-evoked scratching produced by LC activation. Its receptor PlexinC1 was expressed by most MrgprA3 pruriceptors and blocking PlexinC1 reduced semaphorin 7A-evoked neuronal responses. Together, these findings identify epidermal LCs as local immune-derived amplifiers that regulate the responsiveness of cutaneous sensory circuits and identify semaphorin 7A as a mediator of LC-induced itch potentiation.

neuroscience↗

Feasible closed-loop stimulation for neural latent dynamics control

Modern neuroscience benefits from powerful computational and experimental methods for studying neural populations, including latent dynamics models that predict behavior with few dimensions. But despite their explanatory utility, latent factors are seldom targeted explicitly with experimental perturbations, leaving causal relationships to behavior and inferred dynamical landscapes untested. A promising solution is closed-loop, multi-channel optogenetic control, which, when paired with model predictions, could steer neural trajectories in real time--a feat impossible for traditional, hand-designed stimulation. However, because closed-loop latent control has not been demonstrated in vivo, the hardware and software requirements remain unclear--particularly the necessary stimulation dimensionality and how limited resources such as implant volume and bandwidth should be allocated between stimulation and recording capabilities. Preliminary experiments would thus help guide ongoing technological development. As large-scale exploration of these design spaces in vivo is prohibitively expensive, we conducted a high-throughput simulation survey using biophysically grounded spiking neural networks. We found that low-dimensional actuation is sufficient: in the reference configuration, ~20% of the stimulation channels achieved ~85% of peak control performance, far fewer than the number of neurons. Furthermore, allocating channels roughly equally between stimulation and recording optimized behavioral control, whereas pairing many electrodes with a single light source--the prevailing practice in experimental labs--performed poorly. Even without heavily optimizing modeling or control, we obtained >60% tracking error reduction and >90% evoked behavior accuracy on average for optimal channel counts. These results held across extensive parameter variations, suggesting that closed-loop latent control is feasible with accessible channel counts and establishing design principles for future tool development and in vivo experiments.

neuroscience↗

Identification of Kinome Biomarkers and Therapeutic Rescue in cGMP-Linked Retinal Degeneration

Inherited retinal degenerations, such as Retinitis Pigmentosa (RP) and Leber's congenital amaurosis (LCA), are major causes of progressive and irreversible vision loss. The large number of genes associated with these disorders makes their clinical and molecular characterization difficult, while systemic biomarkers for disease progression or treatment response remain limited. These challenges were addressed by targeting cGMP-associated mechanisms shared by RP and LCA and integrating systemic biomarker profiling with retinal outcomes. Kinase activity analysis (kinome analysis) in peripheral blood mononuclear cells distinguished healthy and diseased states and captured therapy-associated signatures in rd10 mice treated with LP-CN03, a liposomal formulation of the cGMP analog CN03. This first systemic analysis in a therapeutically responsive animal model highlights kinome analysis as a potential translational readout. Given shared cGMP signaling in RP and AIPL1-associated LCA, LP-CN03's therapeutic potential was further evaluated in a new CRISPR-Cas9-generated Aipl1-/- mouse model. Treatment with LP-CN03 preserved retinal structure and function, as shown by electroretinography, longitudinal optical coherence tomography, fundus imaging, optomotor testing, and photoreceptor-specific gene expression. Together, these findings provide independent in vivo evidence for the neuroprotective effect of LP-CN03 in both cGMP-related RP and LCA, also highlighting the translational value of kinome profiling.

neuroscience↗